Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
322.14
-3.16 (-0.97%)
Jul 27, 2026, 2:32 PM EDT - Market open
Praxis Precision Medicines Employees
Praxis Precision Medicines had 168 employees as of December 31, 2025. The number of employees increased by 52 or 44.83% compared to the previous year.
Employees
168
Change (1Y)
52
Growth (1Y)
44.83%
Revenue / Employee
n/a
Profits / Employee
-$1,943,649
Market Cap
8.98B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 168 | 52 | 44.83% | 168 | 0 |
| Dec 31, 2024 | 116 | 34 | 41.46% | 116 | 0 |
| Dec 31, 2023 | 82 | -27 | -24.77% | 82 | 0 |
| Dec 31, 2022 | 109 | -30 | -21.58% | 109 | 0 |
| Dec 31, 2021 | 139 | 72 | 107.46% | 139 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,402 |
| Corcept Therapeutics | 730 |
| Crinetics Pharmaceuticals | 594 |
| Halozyme Therapeutics | 423 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Krystal Biotech | 295 |
| Apogee Therapeutics | 261 |
PRAX News
- 14 days ago - Praxis Precision initiated with a Buy at Goldman Sachs - TheFly
- 20 days ago - Praxis Precision, Remagine Labs announce research collaboration and license pact - TheFly
- 20 days ago - Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - GlobeNewsWire
- 24 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies - GlobeNewsWire
- 4 weeks ago - Praxis Precision price target raised to $575 from $510 at Needham - TheFly
- 5 weeks ago - Praxis Precision granted breakthrough therapy designation for elsunersen - TheFly
- 5 weeks ago - Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants - GlobeNewsWire